146. Oncogene. 2018 Jul 23. doi: 10.1038/s41388-018-0370-5. [Epub ahead of print]A SIRT1-centered circuitry regulates breast cancer stemness and metastasis.Shi L(1)(2)(3), Tang X(1)(2)(4), Qian M(1)(2)(4), Liu Z(1)(2)(4), Meng F(1)(2),Fu L(1)(2), Wang Z(1)(4), Zhu WG(1)(4), Huang JD(3), Zhou Z(3), LiuB(5)(6)(7)(8).Author information: (1)Guangdong Key Laboratory for Genome Stability and Human Disease Prevention,Shenzhen University Health Science Center, Shenzhen, 518060, China.(2)Medical Research Center (MRC), Shenzhen University Health Science Center,Shenzhen, 518060, China.(3)School of Biomedical Sciences, LKS Faculty of Medicine, the University of HongKong, Hong Kong, Hong Kong.(4)Department of Biochemistry & Molecular Biology, Shenzhen University HealthScience Center, Shenzhen, 518060, China.(5)Guangdong Key Laboratory for Genome Stability and Human Disease Prevention,Shenzhen University Health Science Center, Shenzhen, 518060, China.ppliew@szu.edu.cn.(6)Medical Research Center (MRC), Shenzhen University Health Science Center,Shenzhen, 518060, China. ppliew@szu.edu.cn.(7)Department of Biochemistry & Molecular Biology, Shenzhen University HealthScience Center, Shenzhen, 518060, China. ppliew@szu.edu.cn.(8)Carson International Cancer Center, Shenzhen University Health Science Center,Shenzhen, 518060, China. ppliew@szu.edu.cn.Cancer stem cell (CSC)-dictated intratumor heterogeneity accounts for themajority of drug-resistance and distant metastases of breast cancers. Here, weidentify a SIRT1-PRRX1-KLF4-ALDH1 circuitry, which couples CSCs,chemo-resistance, metastasis and aging. Pro-longevity protein SIRT1 deacetylates and stabilizes the epithelial-to-mesenchymal-transition (EMT) inducer PRRX1,which inhibits the transcription of core stemness factor KLF4. Loss of SIRT1destabilizes PRRX1, disinhibits KLF4, and activates the transcription of ALDH1,which induces and functionally marks CSCs, resulting in chemo-resistance andmetastatic relapse. Clinically, the level of PRRX1 is positively linked to SIRT1,whereas KLF4 is reversely correlated. Importantly, KLF4 inhibitor Kenpaullonesensitizes breast cancer cells and xenograft tumors to Paclitaxel and improvestherapeutic effects. Our findings delineate a SIRT1-centered circuitry thatregulates CSC origination, and targeting this pathway might be a promisingtherapeutic strategy.DOI: 10.1038/s41388-018-0370-5 PMID: 30038266 